Inogen, Inc.

Report azionario NasdaqGS:INGN

Capitalizzazione di mercato: US$174.6m

Inogen Crescita futura

Criteri Future verificati 0/6

Si prevede che Inogen aumenterà gli utili e i ricavi rispettivamente del 51.4% e 6.3% all'anno, mentre si prevede che l'EPS crescerà del 36.6% all'anno.

Informazioni chiave

51.4%

Tasso di crescita degli utili

36.64%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.1%
Tasso di crescita dei ricavi6.3%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento15 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • May 09

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Analysts have trimmed their price target on Inogen from about $13.00 to roughly $12.67, reflecting updated assumptions around revenue, profit margins and future P/E following fresh bullish initiation research from the Street. Analyst Commentary Analysts are using the fresh bullish initiation as a chance to refresh their models, focus on execution and reassess how much they are willing to pay for Inogen at the current P/E.
Aggiornamento della narrazione • Apr 19

INGN: Buybacks And New Leadership Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.
Aggiornamento della narrazione • Apr 04

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).
Aggiornamento della narrazione • Mar 21

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power

Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).
Aggiornamento della narrazione • Mar 06

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside

Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).
Aggiornamento della narrazione • Feb 20

INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power

Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.
Aggiornamento della narrazione • Feb 06

INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares

Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.
Aggiornamento della narrazione • Jan 22

INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead

Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.
Aggiornamento della narrazione • Jan 08

INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence

Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).
Aggiornamento della narrazione • Dec 16

INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead

Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.
Aggiornamento della narrazione • Dec 02

INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve

Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.
Aggiornamento della narrazione • Nov 18

INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging

Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.
Seeking Alpha • Nov 11

Slow Progress At Inogen ... But Progress All The Same

Summary Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company’s strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions. Valuation appears deeply discounted, with net cash and little credit for progress; INGN offers speculative upside for risk-tolerant investors if improvements persist. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Nov 03

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.
Aggiornamento della narrazione • Oct 20

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.
Aggiornamento della narrazione • Oct 05

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.
Articolo di analisi • Aug 31

There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

The Inogen, Inc. ( NASDAQ:INGN ) share price has done very well over the last month, posting an excellent gain of 29...
Aggiornamento della narrazione • Aug 10

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).
Articolo di analisi • May 10

Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report

A week ago, Inogen, Inc. ( NASDAQ:INGN ) came out with a strong set of quarterly numbers that could potentially lead to...
User avatar
Nuova narrazione • Apr 01

Yuwell Collaboration Will Open Chinese Respiratory Market

Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.
Articolo di analisi • Mar 08

Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

Inogen, Inc. ( NASDAQ:INGN ) shareholders won't be pleased to see that the share price has had a very rough month...
Seeking Alpha • Mar 01

A Volatile Share Price Masks Some Of The Progress At Inogen

Summary Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. Key recent developments include FDA approval of the Simeox device and a strategic partnership with Yuwell, both offering long-term growth potential but requiring time to ramp. While 2024 progress is promising and the valuation is not at all demanding, significant risks remain, particularly in revenue acceleration and margin leverage, making Inogen a high-risk but intriguing speculative investment. Read the full article on Seeking Alpha
Articolo di analisi • Feb 28

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Shareholders in Inogen, Inc. ( NASDAQ:INGN ) had a terrible week, as shares crashed 23% to US$7.95 in the week since...
Articolo di analisi • Jan 22

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Inogen, Inc. ( NASDAQ:INGN ) shareholders would be excited to see that the share price has had a great month, posting a...
Seeking Alpha • Sep 24

Inogen: Upside Seems Limited After Big Move Up

Summary Inogen, Inc. manufactures portable oxygen concentrators and related accessories. The shares have doubled over the past year, but the equity is still trading at roughly 75% of annual sales. Despite an earnings beat in Q2, Wall Street analysts are cautious about the stock's current prospects. Inogen boasts a strong balance sheet with over $120 million in cash (which is roughly half the stock's market cap) and no long-term debt. An analysis of Inogen follows in the paragraphs below. Read the full article on Seeking Alpha
Articolo di analisi • Jul 16

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 26% in the...
Seeking Alpha • Jul 01

Inogen: Improving, But Still Struggling For Air

Summary Inogen aims to help millions suffering from COPD with portable oxygen delivery machines, but its financial performance has been inconsistent. Inogen faced execution issues, but recent improvements in operating momentum due to competitor exits and new management team are sparking optimism. Recent revenue growth, cost cuts, and narrowing losses are encouraging, but shares remain highly speculative and further progress is needed for a more positive outlook. Read the full article on Seeking Alpha
Articolo di analisi • May 22

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Inogen, Inc. ( NASDAQ:INGN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...
Seeking Alpha • Apr 13

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Summary Inogen has continued to struggle, with growth in the rental business overshadowed by declines in direct-to-consumer sales, volatility in business-to-business sales, and pricing pressures. Inogen has the opportunity to leverage the exit of a major competitor, Philips, from the portable oxygen concentrator (POC) market. The new management team aims to position Inogen as the premium POC provider and partner with home medical equipment companies, while also focusing on the Physio-Assist opportunity. Inogen shares trade at a steep discount, but the Street typically wants nothing to do with low-growth small-cap med-tech, so management must present a credible plan for meaningful sustained growth. Read the full article on Seeking Alpha
Articolo di analisi • Mar 01

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

There's been a major selloff in Inogen, Inc. ( NASDAQ:INGN ) shares in the week since it released its annual report...
Articolo di analisi • Feb 01

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 25% in the...

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:INGN - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028417-100192
12/31/2027397-131183
12/31/2026369-22-593
3/31/2026351-25-10-1N/A
12/31/2025349-23-22-11N/A
9/30/2025347-25-24-13N/A
6/30/2025343-26-22-8N/A
3/31/2025340-27-21-6N/A
12/31/2024336-36-116N/A
9/30/2024332-53-146N/A
6/30/2024327-92-201N/A
3/31/2024322-97-26-2N/A
12/31/2023316-102-30-3N/A
9/30/2023328-133-43-16N/A
6/30/2023349-96-55-27N/A
3/31/2023369-90-50-26N/A
12/31/2022377-84-59-38N/A
9/30/2022366-50-36-16N/A
6/30/2022353-28-31-9N/A
3/31/2022351-20-203N/A
12/31/2021358-6024N/A
9/30/202135611933N/A
6/30/2021337-22043N/A
3/31/2021307-51939N/A
12/31/2020308-61937N/A
9/30/2020313-21630N/A
6/30/202033162938N/A
3/31/2020360143643N/A
12/31/201936221N/A41N/A
9/30/201937032N/A44N/A
6/30/201937342N/A43N/A
3/31/201936946N/A46N/A
12/31/201835852N/A60N/A
9/30/201833541N/A61N/A
6/30/201830932N/A64N/A
3/31/201827626N/A60N/A
12/31/201724921N/A60N/A
9/30/201723727N/A53N/A
6/30/201722225N/A44N/A
3/31/201721224N/A39N/A
12/31/201620321N/A31N/A
9/30/201619219N/A38N/A
6/30/201617917N/A41N/A
3/31/201616813N/A37N/A
12/31/201515912N/A38N/A
9/30/20151489N/A30N/A
6/30/20151369N/A21N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che INGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che INGN rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che INGN rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di INGN ( 6.3% all'anno) crescerà più lentamente rispetto al mercato US ( 11.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di INGN ( 6.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di INGN è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/20 19:46
Prezzo dell'azione a fine giornata2026/05/20 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Inogen, Inc. è coperta da 9 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Anderson SchockB. Riley Securities, Inc.
Ilya ZubkovFreedom Broker
Matthew MishanKeyBanc Capital Markets Inc.